Back

Leveraging BRG1 Driven Ferroptosis Resistance to Overcome Treatment Resistance

Hwang, S.-Y.; Nikolli, H.; Yoval-Sanchez, B.; Yang, S.; Martin, P.; Gribbin, C.; Sehgal, L.; Alinari, L.; Baiocchi, R. A.; Hwang, I.; Huang, X.; DiLiberto, M.; Galkin, A.; Kwak, H.; Chen-Kiang, S.; Zheng, H.; Paik, J.

2025-09-05 cancer biology
10.1101/2025.09.02.673601 bioRxiv
Show abstract

Resistance to Brutons tyrosine kinase inhibitors (BTKi) remains a major therapeutic challenge in B-cell malignancies, limiting treatment durability. Here, we identify ferroptosis suppression as a central mechanism of BTKi resistance in mantle cell lymphoma (MCL). Aberrant BRG1 activity protects cells from BTKi-induced ferroptosis by restricting reactive oxygen species (ROS) and labile iron. Mechanistically, BRG1 promotes resistance through both BTK-dependent survival signaling and a BTK-independent transcriptional program. The latter is mediated by BRG1-driven induction of MEF2B, which upregulates NDUFA4L2 to inhibit mitochondrial respiration, thereby blocking mitochondria-dependent ferroptosis. Pharmacologic inhibition of BRG1 disrupts these programs, restoring ferroptotic sensitivity and synergizing with BTKi across resistant MCL models. Together, these findings establish BRG1 as a central regulator of therapy resistance and provide a rationale for co-targeting BRG1 and BTK as a therapeutic strategy for B-cell malignancies.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 10%
18.2%
Similar papers in this journal
2
Cell Death & Differentiation
○ 48 papers in training set
Top 0.1%
9.6%
Similar papers in this journal
3
Cell Death & Disease
147 papers in training set
Top 0.3%
6.2%
4
Molecular Cell
○ 350 papers in training set
Top 1%
6.2%
Similar papers in this journal
5
Science Advances
● 1243 papers in training set
Top 4%
5.4%
Similar papers in this journal
6
Blood
● 74 papers in training set
Top 0.4%
5.4%
50% of probability mass above
7
Cancer Discovery
● 66 papers in training set
Top 0.6%
4.3%
8
Nature Cell Biology
○ 118 papers in training set
Top 0.7%
4.3%
9
Cell Reports
○ 1498 papers in training set
Top 10%
4.0%
10
eLife
● 5828 papers in training set
Top 38%
3.1%
11
Journal of Experimental Medicine
● 119 papers in training set
Top 1%
2.4%
12
Cell
○ 431 papers in training set
Top 5%
2.1%
13
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 26%
1.9%
14
EMBO Reports
○ 263 papers in training set
Top 4%
1.5%
15
Communications Biology
○ 993 papers in training set
Top 18%
1.4%
16
Cancer Research
● 130 papers in training set
Top 3%
1.1%
17
EMBO Molecular Medicine
○ 95 papers in training set
Top 2%
1.1%
18
Nature Cancer
○ 39 papers in training set
Top 1%
1.1%
19
Journal of Clinical Investigation
● 179 papers in training set
Top 4%
1.1%
20
Advanced Science
○ 286 papers in training set
Top 7%
1.1%
21
Cell Chemical Biology
○ 94 papers in training set
Top 1%
1.0%
22
Redox Biology
○ 70 papers in training set
Top 1%
0.9%
23
Cell Reports Medicine
○ 153 papers in training set
Top 5%
0.8%
24
Haematologica
● 25 papers in training set
Top 0.6%
0.8%
25
Immunity
○ 67 papers in training set
Top 2%
0.8%
26
The EMBO Journal
○ 309 papers in training set
Top 8%
0.6%
27
Cell Metabolism
○ 57 papers in training set
Top 2%
0.6%
28
JCI Insight
● 277 papers in training set
Top 9%
0.6%
29
iScience
○ 1154 papers in training set
Top 42%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.